[The relationship between chest CT findings and viral load in XXXX with novel influenza A (H1N1)].

@entity1 @entity3329 @entity55 @entity281 @entity358 @entity456
OBJECTIVE: To evaluate the value of chest CT findings and dynamic changes of viral load in @entity1 with novel @entity281 in clinical diagnosis, differential diagnosis and treatment. METHODS: Fifty-one @entity1 with confirmed novel influenza A (H1N1) according to the diagnostic criteria of the Ministry of Health, received chest X-ray, CT scans (HRCT) and viral load tests in our hospital from May to December of 2009. Based on whether there were signs of @entity55 in CT imaging, the @entity1 were divided into a @entity55 group (n = 31) and a @entity55 group (n = 20). The relationship between chest CT changes and viral load was observed and analyzed statistically using SPSS 10.5 software. RESULTS: Patchy consolidations of lungs were the main findings in @entity55 group with @entity281 , and ground-glass opacities were the main CT findings at acute and convalescent phases. Lobular and segmental shadows of the lungs were diffusely distributed, mostly found in lower lungs, especially the left lung. In some cases, the @entity358 were accompanied with @entity3329 . Co-existence of pulmonary parenchymal, interstitial and @entity456 was observed. Peak viral load occurred at the early phase of illness, with the mean initial viral load being 7.7 copies/ml and 4.2 copies/ml in the @entity55 and the @entity55 groups respectively. The viral nucleic acid became negative 4 days after antiviral treatment (course of 6 days). Dynamic observation of 3 @entity1 with novel @entity55 showed that, the viral clearance period preceded the absorption of lung lesions in 2 cases, but viral clearance period of a young @entity1 was significantly prolonged. CONCLUSION: In @entity1 with the novel @entity281 , the viral load in the @entity55 group was significantly higher than that in the group with normal chest imaging. Dynamic observation on chest imaging and viral load may be beneficial for clinicians to start prompt and effective treatment.
